Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 8, 2025 • 3:00 AM ET

Date/Time Source News Release
07/07/2025 08:15 AM EDT Business Wire Aditxt Unveils bitXbio(TM): A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
06/26/2025 08:15 AM EDT Business Wire Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
06/09/2025 08:15 AM EDT Business Wire Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
06/05/2025 08:15 AM EDT Business Wire Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
05/19/2025 08:00 AM EDT GlobeNewswire Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
05/19/2025 08:00 AM EDT Business Wire Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
05/02/2025 09:00 AM EDT Business Wire Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt(TM), and Dr. Friedrich Kapp, Co-CEO of Adimune(TM), to Discuss Progress of Lead Therapeutic Candidate ADI-100(TM)
04/17/2025 09:08 PM EDT Business Wire KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
04/17/2025 09:03 PM EDT Business Wire KILL Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
04/17/2025 08:15 AM EDT Business Wire Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
Page

Additional News

As of July 8, 2025 • 3:00 AM ET

Date/Time Source News Release
06/26/2025 09:45 AM EDT InvestorWire InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter's NEXT SUPER STOCK Event June 26
06/20/2025 05:14 PM EDT SeekingAlpha Aditxt files to sell up to 50M shares of common stock for holders
06/09/2025 10:30 AM EDT TinyGems TinyGemsBreaks - Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors 
05/19/2025 09:57 AM EDT SeekingAlpha Aditxt to terminate arrangement agreement with Appili Therapeutics
05/19/2025 09:15 AM EDT BioMedWire BioMedNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics 
05/17/2025 05:31 AM EDT US Earnings Reports Expected earnings - Aditxt Inc.
05/02/2025 09:40 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
04/17/2025 10:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic's Dr. Charles Howe in May 2 Update on ADI-100(TM) Preclinical Study
04/16/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
04/14/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100
Page